Announced Wed, 30 Sept, 2026 · 20:09 IST
Knovea signs exclusive US commercialization deal for two DCV injectables with global pharma major
SYMBIOTEC · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Price reaction · full curve 14 horizons · vs prior close
-1.1%1-day move
₹1179.55
prior close
₹1194.00
base price
After-mkt
timing
5m10m15m30m1D2D3D4D5D7D15D1M2M3M
-2.1-2.2-1.8+1.6-1.1-2.3-4.4-7.1——————
Up moveDown movePending
AI summary
Knovea Pharmaceutical, Symbiotec's wholly owned subsidiary, signed a definitive deal with a leading global pharma company (name undisclosed) for exclusive US rights to two Dual Chamber Vial injectable products. Knovea handles development, manufacturing and supply; the partner drives US distribution. Deal includes milestone payments plus profit-sharing post-launch. Target US market is around US$288 million.
Likely market impact
Positive: Knovea gets US market access for two injectable products worth about US$288 million, with milestone payments and profit-sharing ahead.